Gene:
FGA
fibrinogen alpha chain

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA429

Details

Cytogenetic Location: chr4 : q31.3 - q31.3
GP mRNA Boundary: chr4 : 155504280 - 155511897
GP Gene Boundary: chr4 : 155501280 - 155521897
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to FGA: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstetrics and gynecology. 2008. Johnson Julia V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations. Human mutation. 2007. Neerman-Arbez Marguerite, et al. PubMed

LinkOuts

Entrez Gene:
2243
OMIM:
105200
134820
202400
UCSC Genome Browser:
NM_000508
RefSeq RNA:
NM_000508
NM_021871
RefSeq Protein:
NP_000499
NP_068657
RefSeq DNA:
AC_000047
AC_000136
NC_000004
NG_008832
NT_016354
NW_001838921
NW_922217
UniProtKB:
FIBA_HUMAN (P02671)
Ensembl:
ENSG00000171560
GenAtlas:
FGA
GeneCard:
FGA
MutDB:
FGA
ALFRED:
LO000359R
HuGE:
FGA
Comparative Toxicogenomics Database:
2243
ModBase:
P02671
HumanCyc Gene:
HS10342
HGNC:
3661

Common Searches